[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335886-105":59,"doc-detail-335886-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","study-of-drug-targets-associated-with-oncogenesis-and-cancer-cell-survival-and-the-therapeutic-activity-of-engineered-ashwagandha-extract-having-differential-withanolide-constitutions-research-findings","Study of Drug Targets Associated With Oncogenesis and Cancer Cell Survival and the Therapeutic Activity of Engineered Ashwagandha Extract Having Differential Withanolide Constitutions - Research Findings","","Ashwagandha (Withania somnifera) is widely used for purported cancer-preventive and therapeutic benefits, yet clinical adoption remains limited due to inconsistent outcomes caused by variable extract composition and active-ingredient constitution. This study evaluates an engineered, standardized ashwagandha extract (Oncowithanib) with a unique fixed portion of active ingredients to support consistent activity. Using the MCF7 cell line, the work tests anti-neoplastic efficacy and identifies drug targets tied to cell-cycle regulation, translation, survival, and apoptosis, reporting dose-dependent viability loss, reduced colony formation, increased Caspase 3 activity, decreased Ki67 and Aurora Kinase A, and suppressed RSK1, Akt1, and mTOR signaling.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/study-of-drug-targets-associated-with-oncogenesis-and-cancer-cell-survival-and-the-therapeutic-activity-of-engineered-ashwagandha-extract-having-differential-withanolide-constitutions-research-findings/335886/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/study-of-drug-targets-associated-with-oncogenesis-and-cancer-cell-survival-and-the-therapeutic-activity-of-engineered-ashwagandha-extract-having-differential-withanolide-constitutions-research-findings/335886.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is ashwagandha use in cancer treatment considered limited clinically?","Question",{"text":112,"@type":113},"Clinical use is limited because therapeutic outcomes can be inconsistent, driven by highly variable composition and constitution of active ingredients in plant extracts.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is Oncowithanib and what was its purpose in this study?",{"text":117,"@type":113},"Oncowithanib is an engineered ashwagandha extract designed with a unique and fixed portion of active ingredients to achieve consistent and effective therapeutic activity.",{"name":119,"@type":110,"acceptedAnswer":120},"What effects did Oncowithanib show in MCF7 cells?",{"text":121,"@type":113},"Oncowithanib reduced cell viability in a dose-dependent manner, impaired colony-forming ability, increased cell death via enhanced Caspase 3 activity, and lowered expression of proliferation markers such as Ki67 and Aurora Kinase A.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335886,1790161495,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Study of Drug Targets Associated With Oncogenesis and Cancer Cell Survival and the Therapeutic Activity of Engineered Ashwagandha Extract Having Differential Withanolide Constitutions  \nIntegrative Cancer Therapies Volume 23: 1–11  \n© The Author(s) 2024  \nArticle reuse guidelines: [sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/15347354231223499](DOI: 10.1177/15347354231223499)[ ](DOI: 10.1177/15347354231223499)[journals.sagepub.com/home/ict](journals.sagepub.com/home/ict)  \nFranco Cavaleri, PhD(c) 1,2*, Sukalpa Chattopadhyay, PhD 1*, Vrushalee Palsule, BSc 1, Pradip Kumar Kar, PhD2, and Ritam Chatterjee, PhD2  \nAbstract  \nAshwagandha (Withania somnifera) has gained worldwide popularity for a multitude of health benefits inclusive of cancerpreventive and curative effects. Despite numerous research data supporting the benefits of this wonder herb, the actual use of ashwagandha for cancer treatment in clinics is limited. The primary reason for this is the inconsistent therapeutic outcome due to highly variable composition and constitution of active ingredients in the plant extract impacting ashwagandha’s pharmacology. We investigate here an engineered yield: an ashwagandha extract (Oncowithanib) that has a unique and fixed portion of active ingredients to achieve consistent and effective therapeutic activity. Using the MCF7 cell line, Oncowithanib was studied for its anti-neoplastic efficacy and drug targets associated with cell cycle regulation, translation machinery, and cell survival and apoptosis. Results demonstrate a dose-dependent decline in Oncowithanibtreated MCF7 cell viability and reduced colony-forming ability. Treated cells showed increased cell death as evidenced by enhancement of Caspase 3 enzyme activity and decreased expressions of cell proliferation markers such as Ki67 and Aurora Kinase A. Oncowithanib treatment was also found to be associated with expressional suppression of key cellular kinases such as RSK1, Akt1, and mTOR in MCF7 cells. Our findings indicate that Oncowithanib decreases MCF7 cell survival and propagation, and sheds light on common drug targets that might be good candidates for the development of cancer therapeutics. Further in-depth investigations are required to fully explore the potency and pharmacology of this novel extract. This study also highlights the importance of the standardization of herbal extracts to get consistent therapeutic activity for the disease indication.  \nKeywords  \nMCF7, ashwagandha, RSK1, Withaferin A, Akt1, mTOR  \nSubmitted April 11, 2023; revised November 21, 2023; accepted December 13, 2023  \nIntroduction  \nCancer is a complex group of diseases driven by multiple factors that need to align in order for the disease to advance. The complex underpinnings of carcinogenesis clearly reveal that family history, environment, viral infection, mental state, and lifestyle can all play dynamic roles in this multigenic disease.1-3 However, cancer mutations in oncogenes or suppressor genes are not black and white determinants of phenotypic expression of cancer4-7 since multiple genes and the result of their expression need to be corrupted or mutated  \n1 Biologic Pharmamedical Research, Surrey, BC, Canada  \n2Cooch Behar Panchanan Barma University, Cooch Behar, West Bengal, India  \n*These authors contributed equally to this work.  \nCorresponding Authors:  \nFranco Cavaleri, Biologic Pharmamedical Research, 688-2397 King George Blvd, White Rock, Surrey, BC V4A 7E9, Canada.  \nEmail: [franco.c@biologic-med.com](franco.c@biologic-med.com)  \nRitam Chatterjee, Cooch Behar Panchanan Barma University, Panchanan Nagar, Vivekananda Street, Cooch Behar, West Bengal 736101, India.  \nEmail: [ritschatt@gmail.com](ritschatt@gmail.com)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons AttributionNonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/","cbCait8oPCEl7axT","https://ap.wps.com/l/cbCait8oPCEl7axT","pdf",1174578,11,"English","# Abstract\n# Keywords\n# Introduction","[{\"question\":\"Why is ashwagandha use in cancer treatment considered limited clinically?\",\"answer\":\"Clinical use is limited because therapeutic outcomes can be inconsistent, driven by highly variable composition and constitution of active ingredients in plant extracts.\"},{\"question\":\"What is Oncowithanib and what was its purpose in this study?\",\"answer\":\"Oncowithanib is an engineered ashwagandha extract designed with a unique and fixed portion of active ingredients to achieve consistent and effective therapeutic activity.\"},{\"question\":\"What effects did Oncowithanib show in MCF7 cells?\",\"answer\":\"Oncowithanib reduced cell viability in a dose-dependent manner, impaired colony-forming ability, increased cell death via enhanced Caspase 3 activity, and lowered expression of proliferation markers such as Ki67 and Aurora Kinase A.\"}]","Study of Drug Targets Associated With Oncogenesis and Cancer Cell Survival and the Therapeutic Activity of Engineered Ashwagandha Extract Having Differential Withanolide Constitutions - Research Findings | PDF",1790012726,28]